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Introduction. To date, no rating scales for detecting apathy in Parkinson’s disease (PD) patients have been validated in Spanish. For
this reason, the aim of this study was to validate a Spanish version of Lille apathy rating scale (LARS) in a cohort of PD patients
from Spain. Participants andMethods. 130 PD patients and 70 healthy controls were recruited to participate in the study. Apathy was
measured using the Spanish version of LARS and the neuropsychiatric inventory (NPI). Reliability (internal consistency, test-retest,
and interrater reliability) and validity (construct, content, and criterion validity) were measured. Results. Interrater reliability was
0.93. Cronbach’s 𝛼 for LARS was 0.81.The test-retest correlation coefficient was 0.97.The correlation between LARS and NPI scores
was 0.61. The optimal cutoff point under the ROC curve was −14, whereas the value derived from healthy controls was −11. The
prevalence of apathy in our population tested by LARS was 42%. Conclusions. The Spanish version of LARS is a reliable and useful
tool for diagnosing apathy in PD patients. Total LARS score is influenced by the presence of depression and cognitive impairment.
However, both disorders are independent identities with respect to apathy.The satisfactory reliability and validity of the scale make
it an appropriate instrument for screening and diagnosing apathy in clinical practice or for research purposes.
1. Introduction
Between 16 and 48% of Parkinson’s disease (PD) patients
develop apathy during the course of the disease [1, 2]. Apathy
supposes a huge impact on the quality of life of the PD
patients and their families [3]. Apathetic patients have a
very important reduction in the activities of daily living
appropriate to their age, independent of other aspects of the
disease. Hence diagnosing this syndrome is clue to evaluate
these patients. Apathy’s rating scales are useful tools for this
and they are important to evaluate future therapeutic inter-
ventions.
A series of rating scales have been proposed to iden-
tify and quantify apathy and to differentiate it from other
disorders, especially depression [4]. In 1991 Marin et al. [5]
proposed the apathy evaluation scale (AES) based on his
conceptual definition of apathy: “lack of motivation not
attributable to diminished level of consciousness, cognitive
impairment, or emotional distress” [6]. Starkstein et al. [7]
adapted and extended Marin’s definition to establish a series
of standardized diagnostic criteria which constituted the
apathy scale (AS). In 1994, Cummings et al. [8] developed a
tool for assessing behavioural disturbances in patients with
dementia, called the Neuropsychiatric Inventory (NPI); it
included one subscale focusing on apathy. In 2002 Robert
et al. extended NPI by specifically measuring “emotional
blunting, lack of initiative, and lack of interest.” This rating
scale was named the apathy inventory (AI) [9]. In addition to
these available tools, item 4 of theUnified Parkinson’s Disease
Rating Scale (UPDRS) has also been used for detecting apathy
[10].
In 2006, Sockeel et al. [11] proposed the Lille apathy rating
scale (LARS) as a tool to detect and quantify apathy and
distinguish it from depression in PD patients. Two years later,
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these authors validated a caregiver-based version of the scale
[12]. LARS was created based onMarin’s AES criteria but also
extended taking into account the pathophysiological pro-
cesses underlying apathy [13].The psychometric properties of
LARSmake it appropriate formeasuring the disorder in these
patients. For this reason, the aim of this study was to validate
a Spanish version of LARS in a cohort of PD patients from
Spain.
2. Participants and Methods
Twohundred participantswere recruited from theMovement
DisorderUnit atHospital Cl´ınico SanCarlos (Madrid, Spain).
The total included 130 individuals in the PD patient group
and 70 healthy controls. PD was diagnosed according to
the United Kingdom Parkinson’s Disease Society Brain Bank
Criteria [14]. Consecutive PD treated patients were recruited
in three months.The control group consisted of caregivers or
patients’ companions who were not diagnosed with PD. The
inclusion criteria to participate in the study were as follows:
age over 18; no acute systemic diseases or central nervous
system disorders such as Alzheimer disease, cerebrovascular
disease or epilepsy; good health during at least the last
three months before recruitment; and no visual, hearing, or
physical impairments. Furthermore, specifically for the con-
trol group, subjects had to score higher than 26 on the 35-
point Mini-Mental Status Examination (MMSE) and less
than 13 on Montgomery-A˚sberg depression rating scale
(MADRS).
Demographic and clinical information from participants
was collected at the time of recruitment and the clinical
diagnostic of apathy was made at this moment for the main
researcher based on the Starkstein and Leentjens’s criteria
of apathy [15]. All patients and control group gave their
informed consent to participate in the study. Procedures were
performed in accordance with guidelines established by the
Ethics Committee at Hospital and the study was accepted for
this committee.
2.1. Lille Apathy Rating Scale. The characteristics of LARS
have been explained elsewhere [11]. Briefly, the scale is
composed of 33 items grouped in 9 domains, or subscales,
which evaluate “reduction in everyday productivity (EP), lack
of interest (INT), lack of initiative (INI), extinction of novelty
seeking (NS) and motivation (M), blunting of emotional
responses (ER), lack of concern (C), poor social life (SL), and
extinction of self-awareness (SA)” [11]. Each itemwas worded
as a simple, clear question to which the participant responded
with a yes or no. The items refer to emotions and activities
performed during the four weeks prior to the interview. The
total LARS score ranges from −36 to +36; higher positive
scores indicate increased degrees of apathy. Dr. Sockeel gave
consent for the preparation of a Spanish version of LARS.
Although published in English [11], the original language of
LARS is French.The standard “forward-backward” procedure
was applied to translate the LARS. Two bilinguals translated
the original scale into Spanish.
Two independent translators then back-translated the
two translated version into English. The translators were
not connected to the study, so comparability and meaning
equivalence were ensured. Using the different versions, the
authors created a provisional Spanish version of the LARS.
An independent professional revised this version. Minor
differences were corrected at this stage by agreement between
the different translations and the final version was made
available.
2.2. Experimental Phases and Additional Scales. In order to
validate LARS, two studies were performed. (1) A pilot study
assessing participants’ item comprehension, the format and
applicability of the scale, and the interrater reliability of
the proposed Spanish version of LARS. With that aim, a
total of 30 PD patients were interviewed individually by two
investigators after being evaluated using the rating scale.
Interrater reliability was measured by calculating the Kappa
coefficient (𝜅) [16]. (2) An experimental study validates the
psychometric properties of the scale and assesses apathy
among subjects. Motor disability and progression of disease
were evaluated in PD patients by means of the UPDRS and
Hoehn and Yahr scale, respectively [17–19]. In addition to
LARS, NPI apathy subscale was used to measure apathy in
PD patients. Controls were evaluated with LARS scale too.
Moreover, all 200 participants (patients and healthy controls)
were assessed for a blinded neuropsychologist for depression,
dementia, and cognitive impairment using MADRS, Mattis
Dementia Rating Scale (MATTIS), Clock Drawing Test, the
assessment of semantic and phonemic fluency, andMEC [20–
22]. In order to determine the test-retest reliability of LARS,
30 of the PD patients repeated the interview 15 days after the
initial session.
2.3. Data and Statistical Analysis. Since tests were admin-
istered by the researcher, 100% of data were fully com-
putable.Themain psychometrics properties, that is, reliability
(determined by internal consistency and test-retest reliability,
interrater reliability) and validity (construct, content, and
criterion validity), were measured for the Spanish version of
LARS. Internal consistency was determined by calculating
the correlationmatrix of the 33 items on the scale (using Pear-
son’s coefficient), Cronbach’s alpha coefficient (𝛼), and split-
half reliability (using the Spearman-Brown formula). Test-
retest reliability was calculated using the intraclass correc-
tion coefficient (ICC) and paired Student’s 𝑡-test. Construct
validity was evaluated by factor extraction using principal
component analysis (PCA). Oblique rotation was performed
to interpret factor loadings. Convergent validity was mea-
sured by analysing Pearson’s correlation between LARS and
NPI scores.The diagnostic accuracy of LARSwas determined
by comparing the total LARS score and the clinical diag-
nosis established by the main researcher based in Starkstein
and Leentjens’s criteria, using a receiver operating character-
istic (ROC) curve and calculating the area under the curve
(AUC).
Sensitivity, specificity, accuracy, and the Kappa coefficient
were measured at those cutoff points on the ROC curve with
an optimal sensitivity and specificity pair. Floor and ceiling
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effects were identified when an item received the minimum
or the maximum scores, respectively, from more than 90%
of participants. The item discrimination index was evaluated
by comparing the score on each item to the total LARS score,
including one-third of both the highest and the lowest scores.
The relationship between apathy (diagnosed according to
the main researcher’s clinical criteria) and depression (deter-
mined by MADRS) or cognitive impairment (by MATTIS)
was measured by two-factor analysis of variance (ANOVA).
The correlation between the total LARS score and demo-
graphic and clinical characteristics of subjects was analysed
using either Pearson (parametric) or Spearman (nonpara-
metric) correlation coefficients. Multiple regression analy-
sis was performed to identify characteristics independently
related to the total LARS score; variables presenting a 𝑃 ≤
0.05 or a correlation coefficient ≥ 0.20 were included in the
univariate analysis. Demographic and clinical characteristics
were compared among PD patients and healthy controls
using Student’s 𝑡-test for continuous variables and the chi-
square test or Fisher’s exact test for categorical ones.The latter
were expressed as frequencies, whereas continuous variables
were expressed as mean ± standard deviation (SD). Statistical
significance was considered when 𝑃 ≤ 0.05. All the statistical
procedures were performed using SPSS 15.0 (IBM, Chicago,
USA).
3. Results
3.1. Pilot Study. The pilot study revealed that participants’
comprehension of items and the format of the scale were
appropriate in this version of LARS. All participants defined
the scale as easy to complete. The mean completion time
was 10.1 ± 0.5 minutes. The Kappa coefficient for interrater
reliability was 0.93 (95% confidence interval, CI 0.86–0.99;
𝑃 < 0.001).
3.2. Experimental Study. The mean age was 71.6 ± 8.1 in PD
patients and 69.4±8.7 years in healthy controls. Demographic
and clinical characteristics of participants are shown in
Table 1. No significant differences were found between the
two groups with regard to age, gender, or education level.The
median time from disease diagnosis was 49.0 months (range:
26.8–113.2). According to the Hoehn and Yahr scale, 26.2% of
PDpatientswere in stage I, 55.4% in II, 16.2% in III, 1.5% in IV,
and 0.8% in stage V. The mean UPDRS part III score (motor
examination) in PD patients was 22.9 ± 10.9. Significant
differences were found between MEC and MADRS scores
from each group (𝑃 < 0.001). Total LARS scores were
different (𝑃 < 0.001) between PD patients (−14.5 ± 9.1) and
healthy controls (−25.0±5.5).The prevalence of apathy in our
PD population tested by LARS was 42%. No apathic controls
tested by LARS were found in this study.
3.3. Psychometric Properties of the Scale. None of the items
presented a ceiling effect; however, a floor effect was found
for items 20, 21, 24, and 32.The lowest index of discrimination
was observed in items 20, 21, 24, 31, 32, and 33. In the study
of internal consistency of the scale, the correlation matrix
revealed low score correlations between items in different
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Figure 1: ROC curve for the variable total score for LARS. LARS
punctuation versus apathy.
domains and high correlations between items in the same
domain. The lowest coefficient was −0.28 (between items 1
and 28), and the highest, 0.45 (between items 15 and 16).
Correlations between items in the same domain showed a
maximum of 0.45 (between items 15 and 16) and a minimum
of −0.10 (between items 30 and 31). LARS Cronbach’s 𝛼 was
0.81, with a mean interitem value of 0.11 ± 0.01. However,
when items 5, 7, 17, 18, 24, 25, 32, or 33 were removed, 𝛼
value increased. The maximum and minimum correlations
between each item and the total score on that item’s sub-
scale were 0.90 and 0.31, respectively. The mean value of
intersubscale correlation was 0.32 ± 0.03 (highest value =
0.71, and lowest = 0.06). Analysis of the correlation between
each subscale score and the total LARS score revealed an 𝛼
value of 0.76 (maximum = 0.71, and minimum = 0.41). The
test-restest correlation coefficient was 0.97 (95% CI: 0.94–
0.99; 𝑃 < 0.001). Similarly, calculating the correlation using
Pearson’s analysis yielded a coefficient of 0.97 (𝑃 < 0.001).
After the PCA, four factors were identified presenting
eight values equal or more than 1 which explained 67.5%
of the total variance. Factor 1, intellectual curiosity (IC),
included the subscales EP, INT, and INI; factor 2, emotion
(E), grouped subscales NS, M, and SL; factor 3, action
initiation (AI), was composed only by subscale C; and factor
4, self-awareness (SA), included subscales SA and ER. Factor
loadings and correlation after oblique rotation are shown
in Table 2. The correlation among LARS and NPI scores
(concurrent validity assessment) was moderate (𝑟 = 0.61).
Specifically, the maximum and minimum correlations with
NPI were found with factors IC (𝑟 = 0.63) and E (𝑟 =
0.24) from LARS, respectively. ROC analysis estimated an
AUC of 0.86 (95% CI: 0.84–0.95, 𝑃 < 0.001). The cutoff
point for an optimal sensitivity and specificity pair was −14
(Table 3). Furthermore, this cutoff presented the maximum
Kappa coefficient (𝜅 = 0.70). The mean LARS score for PD
patients was −14.51 ± 9.15 and for healthy controls, −25.00 ±
5.52 (Figure 1). Calculating patients’ cutoff value from
the total LARS score with respect to the healthy controls (2.5
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Table 1: Demographic and clinical characteristics of PD patients and healthy controls.
PD patients
(𝑛 = 130)
Healthy controls
(𝑛 = 70)
Age (years), mean ± SD 71.6 ± 8.1 69.4 ± 8.7
Gender, male/female 78/52 39/31
Education level, 𝑛 (%)
No studies 15 (11.5) 13 (18.6)
Primary 82 (63.1) 38 (54.3)
Secondary 25 (19.2) 12 (17.1)
High 8 (6.2) 7 (10.0)
Duration of disease, median months (range) 49 (26.8–113.2)
Hoenh and Yahr scale, 𝑛 (%)
Stage I 34 (26.2)
Stage II 72 (55.4)
Stage III 21 (16.2)
Stage IV 2 (1.5)
Stage V 1 (0.8)
UPDRS score, mean ± SD
Part I 2.9 ± 2.3
Part II 7.8 ± 5.7
Part III 22.9 ± 10.9
Part IV 1.6 ± 3.2
MEC score, mean ± SD 30.7 ± 3.8 33.3 ± 1.7∗
MADRS score, mean ± SD 8.6 ± 4.6 2.9 ± 3.7∗
LARS score, mean ± SD −14.5 ± 9.1 −25.0 ± 5.5∗
MATTIS score, mean ± SD 127 ± 14
NPI, median ± SD 1.6 ± 2.1
Semantic fluency score, mean ± SD 14.4 ± 4.8
Phonemic fluency score, mean ± SD 9.1 ± 4.8
Clock Drawing Test score, mean ± SD 8.9 ± 2.2
PD: Parkinson’s disease; SD: standard deviation; UPDRS: Unified Parkinson Disease Rating Scale; NPI: neuropsychiatric inventory; LARS: Lille apathy rating
scale; MEC: Mini-Mental State Examination; MADRS: Montgomery and A˚sberg depression rating scale; MATTIS: Mattis Dementia Rating Scale. ∗Significant
differences between both groups, 𝑃 < 0,001.
SD points below their mean score) yielded a value of −11. So;
values higher than −14 are indicative of apathy.
On the other hand, total LARS scores have been shown
to depend significantly (𝑃 = 0.033) on the presence of
depression (mean score −9.82 ± 2.14) or nondepression
(−14.66±0.67). Similarly, the total score showed dependence
(𝑃 = 0.002) on the presence of cognitive impairment (mean
score −10.80) or its absence (−15.36). However, the interac-
tions between apathy diagnosis and depression or cognitive
impairment were not significant in either case. Therefore,
apathy is independent of both disorders.
Analysis of correlations between the total LARS score
and the demographic and clinical characteristics of subjects
showed that only age, Hoenh and Yahr stage, UPDRS (parts
I, II, and III), MADRS, and MATTIS presented significant
correlations (𝑃 ≤ 0.05). The highest value was found in
UPDRS part I (𝑟 = 0.58) as is shown in Table 4. Patient char-
acteristics included in the multiple regression model were
Hoehn and Yahr stage, UPDRS parts I and III, MADRS,
MATTIS, and age. These variables explained 34.36% of the
variance of themodel (adjusted𝑅 = 0.46;𝑃 < 0.001, Table 5).
Only UPDRS part I, MADRS, and MATTIS presented an
independent and significant correlation with total score of
LARS which was positive in the case of UPDRS part I (𝛽 =
0.91, 𝑃 = 0.010) and MADRS (𝛽 = 0.40, 𝑃 = 0.001) and
negative for MATTIS (𝛽 = −0.19, 𝑃 = 0.002).
4. Discussion
LARS is a novel instrument able to identify apathy in patients
and differentiate it from depression [11, 23]. To date, only one
apathy rating scale has been validated in Spanish and in a
cohort of patients from Spain [24]. Data from the present
study confirm the efficacy of the Spanish version of LARS for
detecting apathy in these patients which provide a new tool
to assess patients with Parkinson’s disease.
Almost all the participants considered the scale to be very
comprehensible and easy to complete. The value of interrater
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Table 2: Factor loadings after oblique rotation and correlation between oblique factors.
Factor 1 (IC) Factor 2 (E) Factor 3 (AI) Factor 4 (SA)
Factor loadings after oblique rotation
EP 0.805 −0.318 0.381 0.033
INT 0.713 0.156 −0.016 −0.049
INI 0.592 0.295 0.087 −0.003
NS 0.249 0.436 0.300 0.077
M 0.214 0.711 −0.214 0.040
SL −0.185 0.851 0.269 −0.043
C 0.222 0.115 0.810 −0.042
ER 0.223 −0.002 −0.298 0.760
SA −0.242 0.018 0.322 0.776
Correlations between oblique factors
IC 1.000 0.381 0.053 0.239
E 0.381 1.000 0.135 0.275
AI 0.053 0.135 1.000 0.158
SA 0.239 0.275 0.158 1.000
EP: everyday productivity; INT: lack of interest; INI: lack of initiative; NS: extinction of novelty seeking; M: motivation; SL: poor social life; C: lack of concern;
ER: blunting of emotional responses; SA: extinction of self-awareness; IC: intellectual curiosity; E: emotion, AI: action initiation.
Table 3: Sensitivity, specificity, and validity indices and cutoff values for LARS with respect to the clinical diagnostic of apathy performed by
the main researcher.
Cutoff point Accuracy Kappa Sensitivity (95% CI) Specificity (95% CI)
≥−13 0.81 0.61 70.0 (57.6–82.4) 90.0 (82.3–97.7)
≥−14 0.85 0.70 80.0 (69.1–91.0) 90.0 (82.3–97.7)
≥−15 0.83 0.67 81.7 (71.0–92.3) 85.7 (76.8–94.6)
CI: 95% confidence interval.
Table 4: Analysis of correlations between the total LARS score and
the demographic and clinical characteristics.
Correlation
𝑟 (𝑃)
Age 0,29 (0,001)
Sex 0,076 (0,797)
Educational level 0,025 (0,333)
Time evolution of PD 0,008 (0,924)
Hoenh and Yahr 0,37 (0,000)
UPDRS I 0,58 (0,000)
UPDRS II 0,19 (0,035)
UPDRS III 0,37 (0,000)
UPDRS IV 0,08 (0,382)
MADRS 0,43 (0,000)
MATTIS −0,47 (0,000)
reliability was 0.93, indicating almost perfect agreement.
Only four items (21, 24, 32, and 33) presented a floor
effect and low discrimination index, probably because these
answersmay be conditioned by common social-demographic
standards.The internal consistency of the scale was high, with
a Cronbach’s 𝛼 value of 0.81 (appropriate for diagnostic pur-
poses) and half-split reliability of 0.82. The mean interitem
correlation was 0.11 ± 0.01. The decrease of 𝛼 observed when
most items were removed from the calculation did not result
in a value inferior to the lower threshold (0.20). Furthermore,
the same decrease observed when removing subscales from
the calculation did not result in an 𝛼 value inferior to
0.70. Internal consistency values obtained in this Spanish
version were similar to those in the original version of LARS
[11]. In general, the scale demonstrates appropriate interitem
correlation, few random errors, and high accuracy. As in the
original version, the scale presented high interrater and test-
retest reliability.The four factors identified after the PCA (IC,
E, AI, and SA) were not constituted by the same subscales
used in the original version [11]; however, factors from both
scales describe the same dimensions of apathy. In the original
version, the authors correlated LARS with AES (𝑟 = 0.87)
to study concurrent validity; factors IC and AI presented the
strongest values. In the present study, the correlation was
performed among LARS and NPI, resulting in a moderate
correlation (𝑟 = 0.61) with good values for IC (𝑟 = 0.30)
and AI (𝑟 = 0.47). The optimal cutoff point under the ROC
curve was −14, whereas the value derived from healthy
controls was −11. From these results it may be assumed that
some patients who are clinically diagnosed with apathy will
not be detected by the scale. For this reason, scores ranging
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Table 5: Multiple regression model.
Factor∗ 𝐵 coefficient Bs coefficient∗ Standard error IC 95% 𝑃
UPDRS I 0,91 0,23 0,35 0,21 a 1,60 0,010
MADRS 0,49 0,25 0,15 0,20 a 0,78 0,001
MATTIS −0,19 −0,29 0,06 −0,31 a −0,07 0,002
Hoehn and Yahr 0,77 0,06 1,20 −1,60 a 3,14 0,519
Age 0,10 0,08 0,08 −0,07 a 0,26 0,242
UPDRS III 0,02 0,23 0,08 −0,15 a 0,18 0,851
∗Sorted by value 𝐵. ∗Standardized coefficient 𝐵.
between −14 and −11 should be considered indicative of slight
degree of apathy. Therefore, subjects presenting scores below
−14 are considered nonapathetic, while scores above −11
indicate moderate/severe apathy. These cutoff values differ
from those in the original version of LARS (−17 to −22
cuttoff range) probably due to different characteristics of
the participants and their cultural differences. Compared to
the original population [11], our PD patients were older;
subjects presented lower MATTIS scores, lower educational
levels, and longer duration of disease.These featuresmight be
characteristic of the Spanish population.Therefore, the cutoff
values given in the present study may be recommendable for
Spanish subjects. More investigations are needed to corrob-
orate this consideration. Regarding other neurological disor-
ders, the total LARS score was found to be influenced by the
presence of depression and cognitive impairment. However,
both disorders were shown to be independent identities with
respect to apathy.
The limitations of the study are that high educational level
patients and PD patients with IV or V of Hoenh and Yahr
are underrepresented. Another limitation is to take like gold
standard to validate the scale the diagnosis of apathy based
on clinical criteria. The literature review does not provide
sufficient data sensitivity and specificity of these diagnostic
criteria. Apathy is still a controversial entity and difficult to
define for many researchers and clinicians. Finally the scale
is administered to the patient; therefore anosognosia can
be a limiting factor in interpretation of the results. Also in
demented patients the difficulty in understanding the items
and anosognosia, too, may be biased patient response. The
authors of the original scale have developed the caregivers’
version of LARS apathy scale [25].The validation of this scale
has also shown very good reliability and validity data. The
most important difference is being found useful in demented
patients.
The prevalence of apathy in our population assessed by
LARS was 42%. This value is in agreement with prevalence
data from the literature [1, 2]. Having a Spanish version
of LARS that has been validated in subjects from Spain
represents a main goal in the management of apathy in
Spanish PD patients.
5. Conclusion
The Spanish version of LARS is a reliable and useful tool for
diagnosing apathy in PD patients. Depression and cognitive
impairment influence the total LARS score; however, both
entities are independent of apathy. The satisfactory reliability
and validity of the scale make it an appropriate instrument
for screening and diagnosing apathy in clinical practice or for
research purposes.
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